title: Pharmacokinetics and residues of enrofloxacin in chickens.
abstract: The pharmacokinetic properties of enrofloxacin were determined in broiler chickens after single IV and orally administered doses of 10 mg/kg of body weight. After IV and oral administrations, the plasma concentration-time graph was characteristic of a two-compartment open model. The elimination half-life and the mean +/- SEM residence time of enrofloxacin for plasma were 10.29 +/- 0.45 and 9.65 +/- 0.48 hours, respectively, after IV administration and 14.23 +/- 0.46 and 15.30 +/- 0.53 hours, respectively, after oral administration. After single oral administration, enrofloxacin was absorbed slowly, with time to reach maximal plasma concentration of 1.64 +/- 0.04 hours. Maximal plasma concentration was 2.44 +/- 0.06 micrograms/ml. Oral bioavailability was found to be 64.0 +/- 0.2%. Statistically significant differences between the 2 routes of administration were found for the pharmacokinetic variables--half-lives of the distribution and elimination phase and apparent volume of distribution and volume of distribution at steady state. In chickens, enrofloxacin was extensively metabolized into ciprofloxacin. Residues of enrofloxacin and the major metabolite ciprofloxacin in fat, kidney, liver, lungs, muscles, and skin were measured in chickens that received an orally administered dose of 10 mg/kg once daily for 4 days. The results indicate that enrofloxacin and ciprofloxacin residues were cleared slowly. Mean muscle, liver, and kidney concentrations of the metabolite ciprofloxacin ranging between 0.020 and 0.075 micrograms/g persisted on day 12 in chickens after dosing. However, at the time of slaughter (12 days), enrofloxacin residues were only detected in liver and mean +/- SEM concentration was 0.025 +/- 0.003 micrograms/g.
authors.affiliation: Department of Toxicology, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Anadón
authors.forename: M R
authors.initials: MR
authors.lastname: Martínez-Larrañaga
authors.forename: M J
authors.initials: MJ
authors.lastname: Díaz
authors.forename: P
authors.initials: P
authors.lastname: Bringas
authors.forename: M A
authors.initials: MA
authors.lastname: Martínez
authors.forename: M L
authors.initials: ML
authors.lastname: Fernàndez-Cruz
authors.forename: M C
authors.initials: MC
authors.lastname: Fernández
authors.forename: R
authors.initials: R
authors.lastname: Fernández
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000378:metabolism*; D002645:Chickens; D004334:Drug Administration Schedule; D004350:Drug Residues / Q000378:metabolism* / Q000493:pharmacokinetics*; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D007275:Injections, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D015363:Quinolones / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics*; D014018:Tissue Distribution
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin